AbCellera Biologics Inc. Basic Shares Outstanding (Weighted Average)
AbCellera Biologics Inc. (ABCL) reported Basic Shares Outstanding (Weighted Average) of 305.56 million shares for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:WeightedAverageNumberOfSharesOutstandingBasic · last filed 2026-08-05
- AbCellera Biologics Inc. weighted average number of shares outstanding, basic for the quarter ending 2026-06-30 was 305.56M shares, a 2.36% increase year-over-year.
- AbCellera Biologics Inc. weighted average number of shares outstanding, basic for the quarter ending 2026-03-31 was 303.07M shares, a 1.81% increase year-over-year.
- AbCellera Biologics Inc. weighted average number of shares outstanding, basic for the quarter ending 2025-12-31 was 299.73M shares, a 1.43% increase year-over-year.
- AbCellera Biologics Inc. weighted average number of shares outstanding, basic for the quarter ending 2025-09-30 was 298.88M shares, a 1.36% increase year-over-year.
- AbCellera Biologics Inc. weighted average number of shares outstanding, basic for fiscal 2025 was 298.71M shares, a 1.49% increase from fiscal 2024.
- AbCellera Biologics Inc. weighted average number of shares outstanding, basic for fiscal 2024 was 294.33M shares, a 1.78% increase from fiscal 2023.
- AbCellera Biologics Inc. weighted average number of shares outstanding, basic for fiscal 2023 was 289.17M shares, a 1.44% increase from fiscal 2022.
- AbCellera Biologics Inc. weighted average number of shares outstanding, basic for fiscal 2022 was 285.06M shares, a 3.37% increase from fiscal 2021.
| Period end | Weighted Average Number of Shares Outstanding, Basic 3 month | Weighted Average Number of Shares Outstanding, Basic 6 month | Weighted Average Number of Shares Outstanding, Basic 9 month | Weighted Average Number of Shares Outstanding, Basic 12 month |
|---|---|---|---|---|
| 2026-06-30 | 305.56M shares 10-Q · filed 2026-08-05 | 304.33M shares 10-Q · filed 2026-08-05 | 302.79M shares derived: average of 3 quarters · filed 2026-08-05 | 301.81M shares derived: average of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | 303.07M shares 10-Q · filed 2026-05-11 | 301.40M shares derived: average of 2 quarters · filed 2026-05-11 | 300.56M shares derived: average of 3 quarters · filed 2026-05-11 | 300.05M shares derived: average of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | 299.73M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | 299.30M shares derived: average of 2 quarters · filed 2026-02-24 | 299.04M shares derived: average of 3 quarters · filed 2026-08-05 | 298.71M shares 10-K · filed 2026-02-24 |
| 2025-09-30 | 298.88M shares 10-Q · filed 2025-11-06 | 298.69M shares derived: average of 2 quarters · filed 2026-08-05 | 298.37M shares 10-Q · filed 2025-11-06 | 297.65M shares derived: average of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | 298.51M shares 10-Q · filed 2026-08-05 | 298.11M shares 10-Q · filed 2026-08-05 | 297.24M shares derived: average of 3 quarters · filed 2026-08-05 | 296.64M shares derived: average of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | 297.69M shares 10-Q · filed 2026-05-11 | 296.61M shares derived: average of 2 quarters · filed 2026-05-11 | 296.02M shares derived: average of 3 quarters · filed 2026-05-11 | 295.57M shares derived: average of 4 quarters · filed 2026-05-11 |
| 2024-12-31 | 295.52M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | 295.18M shares derived: average of 2 quarters · filed 2026-02-24 | 294.86M shares derived: average of 3 quarters · filed 2026-02-24 | 294.33M shares 10-K · filed 2026-02-24 |
| 2024-09-30 | 294.85M shares 10-Q · filed 2025-11-06 | 294.53M shares derived: average of 2 quarters · filed 2025-11-06 | 293.93M shares 10-Q · filed 2025-11-06 | 293.05M shares derived: average of 4 quarters · filed 2026-02-24 |
| 2024-06-30 | 294.22M shares 10-Q · filed 2025-08-07 | 293.47M shares 10-Q · filed 2025-08-07 | 292.45M shares derived: average of 3 quarters · filed 2026-02-24 | 291.71M shares derived: average of 4 quarters · filed 2026-02-24 |
| 2024-03-31 | 292.72M shares 10-Q · filed 2025-05-08 | 291.57M shares derived: average of 2 quarters · filed 2026-02-24 | 290.88M shares derived: average of 3 quarters · filed 2026-02-24 | 290.39M shares derived: average of 4 quarters · filed 2026-02-24 |
| 2023-12-31 | 290.41M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | 289.96M shares derived: average of 2 quarters · filed 2026-02-24 | 289.61M shares derived: average of 3 quarters · filed 2026-02-24 | 289.17M shares 10-K · filed 2026-02-24 |
| 2023-09-30 | 289.50M shares 10-Q · filed 2024-11-04 | 289.20M shares derived: average of 2 quarters · filed 2024-11-04 | 288.75M shares 10-Q · filed 2024-11-04 | 288.12M shares derived: average of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | 288.91M shares 10-Q · filed 2024-08-06 | 288.36M shares 10-Q · filed 2024-08-06 | 287.66M shares derived: average of 3 quarters · filed 2025-02-27 | 287.08M shares derived: average of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | 287.77M shares 10-Q · filed 2024-05-07 | 287.04M shares derived: average of 2 quarters · filed 2025-02-27 | 286.47M shares derived: average of 3 quarters · filed 2025-02-27 | 286.02M shares derived: average of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | 286.31M shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | 285.82M shares derived: average of 2 quarters · filed 2025-02-27 | 285.44M shares derived: average of 3 quarters · filed 2025-02-27 | 285.06M shares 10-K · filed 2025-02-27 |
| 2022-09-30 | 285.32M shares 10-Q · filed 2023-11-02 | 285.00M shares derived: average of 2 quarters · filed 2023-11-02 | 284.64M shares 10-Q · filed 2023-11-02 | 284.01M shares derived: average of 4 quarters · filed 2024-02-20 |
| 2022-06-30 | 284.69M shares 10-Q · filed 2023-08-03 | 284.29M shares 10-Q · filed 2023-08-03 | 283.57M shares derived: average of 3 quarters · filed 2024-02-20 | 282.41M shares derived: average of 4 quarters · filed 2024-02-20 |
| 2022-03-31 | 283.90M shares 10-Q · filed 2023-05-04 | 283.01M shares derived: average of 2 quarters · filed 2024-02-20 | 281.65M shares derived: average of 3 quarters · filed 2024-02-20 | 279.29M shares derived: average of 4 quarters · filed 2024-02-20 |
| 2021-12-31 | 282.13M shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-20 | 280.53M shares derived: average of 2 quarters · filed 2024-02-20 | 277.75M shares derived: average of 3 quarters · filed 2024-02-20 | 275.76M shares 10-K · filed 2024-02-20 |
| 2021-09-30 | 278.93M shares 10-Q · filed 2022-11-08 | 275.56M shares derived: average of 2 quarters · filed 2022-11-08 | 273.64M shares 10-Q · filed 2022-11-08 | 250.09M shares derived: average of 4 quarters · filed 2023-02-21 |
| 2021-06-30 | 272.20M shares 10-Q · filed 2022-08-09 | 270.95M shares 10-Q · filed 2022-08-09 | 240.48M shares derived: average of 3 quarters · filed 2023-02-21 | 218.62M shares derived: average of 4 quarters · filed 2023-02-21 |
| 2021-03-31 | 269.70M shares 10-Q · filed 2022-05-10 | 224.62M shares derived: average of 2 quarters · filed 2023-02-21 | 200.76M shares derived: average of 3 quarters · filed 2023-02-21 | 188.65M shares derived: average of 4 quarters · filed 2023-02-21 |
| 2020-12-31 | 179.54M shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-21 | 166.29M shares derived: average of 2 quarters · filed 2023-02-21 | 161.64M shares derived: average of 3 quarters · filed 2023-02-21 | 159.20M shares 10-K · filed 2023-02-21 |
| 2020-09-30 | 153.05M shares 10-Q · filed 2021-11-10 | 152.69M shares derived: average of 2 quarters · filed 2021-11-10 | 152.41M shares 10-Q · filed 2021-11-10 | |
| 2020-06-30 | 152.33M shares 10-Q · filed 2021-08-13 | 152.09M shares 10-Q · filed 2021-08-13 | ||
| 2020-03-31 | 151.86M shares 10-Q · filed 2021-05-14 | |||
| 2019-12-31 | 151.33M shares 10-K · filed 2022-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |